IL129475A0 - Neurotrophin antagonist compositions - Google Patents
Neurotrophin antagonist compositionsInfo
- Publication number
- IL129475A0 IL129475A0 IL12947597A IL12947597A IL129475A0 IL 129475 A0 IL129475 A0 IL 129475A0 IL 12947597 A IL12947597 A IL 12947597A IL 12947597 A IL12947597 A IL 12947597A IL 129475 A0 IL129475 A0 IL 129475A0
- Authority
- IL
- Israel
- Prior art keywords
- loweralkyl
- neurotrophin
- carboxy
- optionally substituted
- mediated activity
- Prior art date
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 title abstract 3
- 102000007072 Nerve Growth Factors Human genes 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000014511 neuron projection development Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9621902.7A GB9621902D0 (en) | 1996-10-21 | 1996-10-21 | Neurotrophin antagonist compositions |
| GBGB9710904.5A GB9710904D0 (en) | 1997-05-27 | 1997-05-27 | Neurotropin antagonist compositions |
| PCT/CA1997/000779 WO1998017278A1 (en) | 1996-10-21 | 1997-10-20 | Neurotrophin antagonist compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL129475A0 true IL129475A0 (en) | 2000-02-29 |
Family
ID=26310264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12947597A IL129475A0 (en) | 1996-10-21 | 1997-10-20 | Neurotrophin antagonist compositions |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20020169182A1 (de) |
| EP (1) | EP0930883B1 (de) |
| JP (1) | JP2001503397A (de) |
| KR (1) | KR20000052691A (de) |
| AT (1) | ATE315397T1 (de) |
| AU (1) | AU728523C (de) |
| BR (1) | BR9712424A (de) |
| CA (1) | CA2268450C (de) |
| DE (1) | DE69735090T2 (de) |
| DK (1) | DK0930883T3 (de) |
| ES (1) | ES2257768T3 (de) |
| IL (1) | IL129475A0 (de) |
| NZ (1) | NZ335291A (de) |
| WO (1) | WO1998017278A1 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2268450C (en) | 1996-10-21 | 2008-08-05 | Allelix Biopharmaceuticals, Inc. | Neurotrophin antagonist compositions |
| SK7012001A3 (en) * | 1998-11-25 | 2001-11-06 | Merck Patent Gmbh | Substituted benzo[de]isoquinoline-1,3-diones |
| CA2352045A1 (en) * | 1998-11-25 | 2000-06-08 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Substituted benzo[de]isoquinoline-1,3-diones |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| US6492380B1 (en) * | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
| FR2807660A1 (fr) * | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| MXPA05003502A (es) | 2002-10-08 | 2005-09-30 | Rinat Neuroscience Corp | Metodo para tratar dolor post-quirurgico al administrar un antagonista del factor de crecimiento de nervios y composiciones que contienen el mismo. |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| NZ540730A (en) | 2002-12-24 | 2010-09-30 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods using same |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| ATE491444T1 (de) | 2003-02-19 | 2011-01-15 | Rinat Neuroscience Corp | Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor- antagonisten und eines nsaid und diese enthaltende zusammensetzung |
| FR2862968B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique |
| FR2862967B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique |
| KR101504729B1 (ko) | 2004-04-07 | 2015-03-19 | 리나트 뉴로사이언스 코프. | 신경성장인자 길항제의 투여에 의한 골암 통증 치료용 약학적 조성물 |
| GB0419850D0 (en) * | 2004-09-07 | 2004-10-13 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| KR20080058403A (ko) * | 2005-09-15 | 2008-06-25 | 페인셉터 파마 코포레이션 | 뉴로트로핀 매개 활성 조절 방법 |
| WO2009039635A1 (en) * | 2007-09-24 | 2009-04-02 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| FR2953839A1 (fr) | 2009-12-14 | 2011-06-17 | Sanofi Aventis | Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75 |
| RS63063B1 (sr) | 2010-08-19 | 2022-04-29 | Zoetis Belgium S A | Anti-ngf antitela i njihova upotreba |
| EP2606894A1 (de) | 2011-12-20 | 2013-06-26 | Sanofi | Neuartige therapeutische Verwendung von p75-Rezeptorantagonisten |
| US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
| AU2019234213A1 (en) | 2018-03-12 | 2020-09-03 | Zoetis Services Llc | Anti-NGF antibodies and methods thereof |
| WO2023212596A1 (en) | 2022-04-27 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US627129A (en) * | 1899-06-20 | Collar-edge-ironing machine | ||
| US525841A (en) * | 1894-09-11 | Baling-press | ||
| US3821383A (en) * | 1972-07-10 | 1974-06-28 | Ayerst Mckenna & Harrison | Compositions for and a method of treating diabetic complications |
| US4006238A (en) * | 1975-08-28 | 1977-02-01 | E. R. Squibb & Sons, Inc. | Use of 2-(hydroxyalkyl)-1H-benz[de]isoquinoline-1,3(2H)-diones as anti-allergy agents |
| ES459497A1 (es) * | 1977-06-04 | 1978-04-16 | Made Labor Sa | Un metodo para la preparacion industrial de naftalimidas y sus derivados. |
| US4254109A (en) * | 1979-11-08 | 1981-03-03 | Ayerst, Mckenna & Harrison Inc. | 1H-Benz[de]isoquinoline-2(3H)-acetic acid derivatives |
| RU2051677C1 (ru) * | 1982-02-10 | 1996-01-10 | Украинский научно-исследовательский институт эндокринологии и обмена веществ | Средство для профилактики и лечения диабетических осложнений, ангиопатий, нейропатий, катаракты |
| US5183821A (en) * | 1983-09-19 | 1993-02-02 | Laboratories Knoll, S.A. | Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors |
| IT1214618B (it) * | 1985-06-27 | 1990-01-18 | I P A International Pharmaceut | Composti e composizioni farmaceutiche per la terapia di retinopatie e neuropatie diabetiche. |
| DE3635711A1 (de) * | 1986-10-21 | 1988-04-28 | Knoll Ag | 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung |
| DE3707652A1 (de) * | 1987-03-10 | 1988-09-22 | Knoll Ag | Verwendung von benzo(de)isochinolin-1,3-dionen zur herstellung von arzneimitteln |
| DE3707651A1 (de) * | 1987-03-10 | 1988-09-22 | Knoll Ag | Bis-naphthalimide, ihre herstellung und verwendung |
| US5420137A (en) * | 1989-07-11 | 1995-05-30 | Knoll Ag | Amonafide salts |
| US5356906A (en) * | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
| CA2030129A1 (en) * | 1989-11-29 | 1991-05-30 | Thomas Saupe | 1,8-napthalenedicarboximides as antidotes |
| US5342942A (en) * | 1992-06-09 | 1994-08-30 | Warner-Lambert Company | Pyrazoloquinazolone derivatives as neurotrophic agents |
| DE4232739A1 (de) * | 1992-09-30 | 1994-03-31 | Knoll Ag | Neue asymmetrisch substituierte bis-Naphthalimide |
| IL110460A (en) * | 1993-08-18 | 2001-01-11 | Basf Ag | Bite-naphthalimides, their preparation and pharmaceutical preparations containing them |
| US6291247B1 (en) * | 1994-05-11 | 2001-09-18 | Queen's University At Kingston | Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity |
| GB9616105D0 (en) * | 1996-07-31 | 1996-09-11 | Univ Kingston | TrkA binding site of NGF |
| CA2268450C (en) | 1996-10-21 | 2008-08-05 | Allelix Biopharmaceuticals, Inc. | Neurotrophin antagonist compositions |
| CA2279331C (en) | 1997-02-07 | 2010-04-20 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| WO1998052919A1 (fr) | 1997-05-21 | 1998-11-26 | Japan Tobacco Inc. | Derives de phtalimide et produit pharmaceutique contenant ces derives |
| WO2000000472A1 (en) | 1998-06-30 | 2000-01-06 | Du Pont Pharmaceuticals Company | 5-ht7 receptor antagonists |
| KR100364205B1 (ko) * | 1998-07-03 | 2002-12-11 | 다이호야쿠힌고교 가부시키가이샤 | 나프탈이미도벤즈아미드 유도체 또는 그의 염 |
| US6468990B1 (en) * | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| US6492380B1 (en) * | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
-
1997
- 1997-10-20 CA CA002268450A patent/CA2268450C/en not_active Expired - Fee Related
- 1997-10-20 BR BR9712424-9A patent/BR9712424A/pt not_active Application Discontinuation
- 1997-10-20 NZ NZ335291A patent/NZ335291A/en unknown
- 1997-10-20 EP EP97909098A patent/EP0930883B1/de not_active Expired - Lifetime
- 1997-10-20 AU AU46968/97A patent/AU728523C/en not_active Ceased
- 1997-10-20 IL IL12947597A patent/IL129475A0/xx not_active IP Right Cessation
- 1997-10-20 AT AT97909098T patent/ATE315397T1/de not_active IP Right Cessation
- 1997-10-20 ES ES97909098T patent/ES2257768T3/es not_active Expired - Lifetime
- 1997-10-20 JP JP51875698A patent/JP2001503397A/ja not_active Ceased
- 1997-10-20 DE DE69735090T patent/DE69735090T2/de not_active Expired - Fee Related
- 1997-10-20 DK DK97909098T patent/DK0930883T3/da active
- 1997-10-20 KR KR1019990703479A patent/KR20000052691A/ko not_active Application Discontinuation
- 1997-10-20 WO PCT/CA1997/000779 patent/WO1998017278A1/en active IP Right Grant
-
2001
- 2001-01-11 US US09/758,917 patent/US20020169182A1/en not_active Abandoned
-
2005
- 2005-07-13 US US11/179,610 patent/US7291629B2/en not_active Expired - Fee Related
-
2007
- 2007-09-28 US US11/905,406 patent/US20080287484A1/en not_active Abandoned
-
2009
- 2009-04-28 US US12/453,032 patent/US20090215815A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20020169182A1 (en) | 2002-11-14 |
| EP0930883A1 (de) | 1999-07-28 |
| WO1998017278A1 (en) | 1998-04-30 |
| EP0930883B1 (de) | 2006-01-11 |
| DE69735090T2 (de) | 2006-09-14 |
| JP2001503397A (ja) | 2001-03-13 |
| US7291629B2 (en) | 2007-11-06 |
| AU728523C (en) | 2001-08-09 |
| CA2268450A1 (en) | 1998-04-30 |
| AU728523B2 (en) | 2001-01-11 |
| AU4696897A (en) | 1998-05-15 |
| US20080287484A1 (en) | 2008-11-20 |
| US20090215815A1 (en) | 2009-08-27 |
| ATE315397T1 (de) | 2006-02-15 |
| ES2257768T3 (es) | 2006-08-01 |
| KR20000052691A (ko) | 2000-08-25 |
| CA2268450C (en) | 2008-08-05 |
| NZ335291A (en) | 2001-02-23 |
| BR9712424A (pt) | 2001-11-20 |
| DE69735090D1 (de) | 2006-04-06 |
| US20050250807A1 (en) | 2005-11-10 |
| DK0930883T3 (da) | 2006-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL129475A0 (en) | Neurotrophin antagonist compositions | |
| HUT76548A (en) | Aryl-sulfonamido-hydroxamic acids of matrix-metalloproteinase-inhibiting activity | |
| MX9709416A (es) | Compuesto tipo quinolizinona. | |
| AU7578894A (en) | Methods for inhibiting smooth muscle cell proliferation and restinosis | |
| WO1996016981A3 (en) | Peptide compounds for prevention and/or treatment of no-mediated diseases | |
| TW376319B (en) | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine | |
| MY132056A (en) | Methods of inhibiting physiological conditions associated with an excess of neuropeptide y. | |
| CA2223625A1 (en) | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors | |
| GEP20064005B (en) | Use of novel benzoimidazole derivatives as antiproliferative agents | |
| AU7578794A (en) | Methods for inhibiting endometriosis | |
| BG103947A (en) | Derivatives of 9-oxymerythromycin | |
| BG104089A (en) | Dolastatine 15 derivatives | |
| PL2017276T3 (pl) | Związki fenylowo-karboksamidowe przydatne do leczenia bólu | |
| EP1140900A4 (de) | Pyrazol verbindungen und ihre verwendung | |
| WO1998046576A3 (en) | Halo-alkoxycarbonyl prodrugs | |
| HU9203286D0 (en) | Inflammation inhibiting hydrosame acids and n-hydroxi-ureas | |
| PH31316A (en) | Method for inhibiting cartilage degradation. | |
| UA37311C2 (uk) | Засіб для лікування статевої дисфункції і фармацевтичний препарат | |
| YU69699A (sh) | Derivati aril karbonske kiseline i tetrazola | |
| TW252979B (de) | ||
| IL148196A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
| ES8505948A1 (es) | Un derivado de amida. | |
| CA2208032A1 (en) | Substituted amidinonaphthyl ester derivative | |
| NZ503027A (en) | Use of rifamycin derivative for treating mastitis in a domestic animal | |
| TR200000753T2 (tr) | Mukabil antifungal ajan için prodrog olarak tetrahidrofuran fosfat ve hidroksi esterleri. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |